PROCEPT BioRobotics (NASDAQ:PRCT) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its earnings results on Monday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09, Briefing.com reports. The firm had revenue of $58.40 million during the quarter, compared to analyst estimates of $53.30 million. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 37.85%. During the same quarter in the prior year, the firm posted ($0.51) EPS. PROCEPT BioRobotics’s revenue was up 66.4% compared to the same quarter last year. PROCEPT BioRobotics updated its FY 2024 guidance to EPS.

PROCEPT BioRobotics Stock Down 3.2 %

PRCT opened at $88.11 on Tuesday. The company has a market capitalization of $4.58 billion, a PE ratio of -44.17 and a beta of 1.03. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.51 and a quick ratio of 6.49. PROCEPT BioRobotics has a fifty-two week low of $24.83 and a fifty-two week high of $91.24. The business has a 50-day moving average of $75.86 and a 200-day moving average of $67.14.

Insider Activity at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 13,305 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the transaction, the director now owns 317,518 shares of the company’s stock, valued at approximately $24,248,849.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $82.51, for a total transaction of $2,062,750.00. Following the sale, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at $7,928,880.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Antal Rohit Desai sold 13,305 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $76.37, for a total value of $1,016,102.85. Following the transaction, the director now owns 317,518 shares in the company, valued at $24,248,849.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,892 shares of company stock valued at $13,946,415. 17.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

PRCT has been the subject of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Truist Financial upped their price target on PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Bank of America boosted their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, TD Cowen lifted their price target on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Buy” and an average target price of $86.40.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).